FDA's GMP Expectations for Phase I and First-in-Man Clinical Trials: 2-day In-person Seminar

Manufacturing an investigational product for the initial pilot clinical trials could pose a considerable logistical and financial challenge to developers. The first-in-man and pilot clinical trials are usually conducted in very small number of healthy participants with lower doses primarily to establish safety and hence do not need a significant amount of investigational material. The US FDA allows developers to test early stage investigational products under relaxed GMP requirements.

The manufacturing requirements for early stage clinical trials are designed to assure adequate quality of the investigational product being tested without the excessive regulatory burden of full-scale GMP manufacturing. This workshop will present the current regulations, guidance documents and regulatory strategies available for manufacturing an early development stage product for Phase I and first-in-man clinical trials. Also discussed will be logistical issues with managing the supply of an early stage investigational product, and requirements for stability testing, storage and shipping, labeling, and documentations. Issues specific to special products in early stages of development such as combination products and 505(b)(2) drugs will be discussed. Basics of process validation along to standard process development will be presented. Perspectives for different classes of products will be presented using case studies.

• Directors
• Managers
• Supervisors, and lead workers in Regulatory Affairs
• Quality Assurance and Quality Control
• Workers who will prepare GMP documents for early phase products as well as those who will review these documents
• Regulatory affairs workers who will need to deal with submissions covering early phase products.